OncoMed Pharma (OMED) Reports In-Line Q3 EPS

November 1, 2016 5:17 PM EDT
Get Alerts OMED Hot Sheet
Trade OMED Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

OncoMed Pharma (NASDAQ: OMED) reported Q3 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $9.48 million.

Cash, cash equivalents and short-term investments totaled $207.6 million as of September 30, 2016, compared to $171.5 million as of June 30, 2016. The company’s cash balance includes net proceeds of $59.2 million from a follow-on offering completed August 23, 2016.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment